Table 2.
Overview of miRNAs with significantly different levels of expression in rectal tumors of responders and non-responders to neoadjuvant chemoradiotherapy
| MiRNAs | R | NR | Fold change (NR vs R) | P-value | Putative targets†# |
|---|---|---|---|---|---|
|
miR-450b-5p |
U |
D |
0.07 |
0.0003 |
RANBP9, SLC19A2, XIAP, RGMB, SMAD2, SERPINA5, SOX2, TCF5, TIMP2, TGFBR2 |
|
let-7e |
U |
D |
0.48 |
0.0075 |
NRAS#, KRAS#, SOCS1#, HMGA2#, ABCC5, HOXD1, MASP1, ERCC6, IGF1 |
|
miR-450a |
U |
D |
0.16 |
0,0104 |
MAP3K2, RAB31, TOPBP1, CREB1, DNMT3A, EGFR, ERCC5 |
|
miR-99a* |
U |
D |
0,21 |
0,0163 |
RAD51C, RAD9B, TIAM1, TMEM87a, TMEM71, SOCS4, RANBP4, RANBP6 |
|
miR-190b |
D |
U |
4.03 |
0.0290 |
CDKN1B, MUC17, MYCBP2, SMAD2, TCF4, CASP2, TP53INP1 |
|
miR-29b-2* |
D |
U |
4.25 |
0.0375 |
AKT3, RANBP9, PARP2, HDAC5, CDKN3, AGR2, SLC19A2, FOXN3 |
|
miR-215 |
D |
U |
4.40 |
0.040 |
ZEB2#, ALCAM#, TYMS (TS) #, DHFR#, EREG, HOXB9, NOD2 |
| miR-196b | U | D | 0.42 | 0,043 | HOXB8#, HOXC8#, ERG#, BACH1#, FAS, TBRG1, TOX3 |
Legend: R – responders, NR – non-responders, D – down-regulated expression, U – up-regulated expression. # Target is experimentally validated. † Putative targets were predicted using miRWalk database and miRanda algorith (21) and subsequently selected on the basis of their significance in tumor biology, particularly in the processes of cell survival and resistance to anti-cancer treatment.